Cancer treatment may inhibit immune response to COVID-19 vaccination


Date:
January 20, 2022
Source:
Mayo Clinic
Summary:
A study has found that patients with cancer who receive chemotherapy
- - and some targeted therapies, such as CDK4/6 inhibitors and
therapies targeted at B cells -- may mount an inadequate immune
response to COVID- 19 vaccination.



FULL STORY ==========================================================================
A study by researchers at Mayo Clinic Cancer Center has found that
patients with cancer who receive chemotherapy -- and some targeted
therapies, such as CDK4/6 inhibitors and therapies targeted at B cells
-- may mount an inadequate immune response to COVID-19 vaccination. The findings are published in Mayo Clinic Proceedings: Innovation, Quality
& Outcomes.


==========================================================================
"It is important for patients with cancer who are receiving chemotherapy
to receive a COVID-19 vaccine," says Saranya Chumsri, M.D., a Mayo Clinic hematologist and oncologist, and author of the paper. Dr. Chumsri says
this advice also applies to patients with cancer who are taking a CDK 4/
6 inhibitors. These inhibitors are a newer class of medicines used to
treat hormone-receptor-positive and HER2-negative breast cancers.

Dr. Chumsri says that while CDK 4/6 inhibitors are not conventionally considered to be as immunosuppressive as chemotherapy, her research on
patients with breast cancer who take these drugs found that they exhibited
less optimal neutralizing antibody activity. Dr. Chumsri recommends
that antibody levels be tested in these patients after vaccination,
and they should consider receiving booster vaccinations for COVID-19.

Dr. Chumsri anticipates having additional data later this year regarding broader immune responses to COVID-19 vaccinations, including cellular
and antibody responses in patients receiving chemotherapy and targeted therapies with booster vaccinations.

========================================================================== Story Source: Materials provided by Mayo_Clinic. Original written by
Joe Dangor. Note: Content may be edited for style and length.


========================================================================== Journal Reference:
1. Saranya Chumsri, Pooja P. Advani, Tanmayi S. Pai, Zhuo Li, Ashita
Mummareddy, Marites Acampora, Gina A. Reynolds, Natasha Wylie,
Ashton W.

Boyle, Yanyan Lou, Kabir Mody, Alvaro Moreno-Aspitia, Melanie
D. Swift, Abinash Virk, Adil E. Bharucha, Christopher P. Marquez,
Tushar C. Patel, Gregory J. Gores, Keith L. Knutson. Humoral
Responses after SARS-CoV- 2 mRNA Vaccination and Breakthrough
Infection in Cancer Patients. Mayo Clinic Proceedings: Innovations,
Quality & Outcomes, 2021; DOI: 10.1016/ j.mayocpiqo.2021.12.004 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2022/01/220120125438.htm

--- up 6 weeks, 5 days, 7 hours, 13 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)